학술논문
Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B-cell lymphoma.
Document Type
Article
Source
Frontiers in Oncology; 1/5/2023, Vol. 13, p1-6, 6p
Subject
Language
ISSN
2234943X